United States, Food and Drug Administration
Resource Information
The concept United States, Food and Drug Administration represents the subject, aboutness, idea or notion of resources found in University of Missouri Libraries.
The Resource
United States, Food and Drug Administration
Resource Information
The concept United States, Food and Drug Administration represents the subject, aboutness, idea or notion of resources found in University of Missouri Libraries.
- Label
- United States, Food and Drug Administration
- Numeration
- Food and Drug Administration
- Subordinate unit
- Food and Drug Administration
100+ Items that share the Concept United States, Food and Drug Administration
Context
Context of United States, Food and Drug AdministrationSubject of
- "Man-in-the-plant" revisited--a deceptive drug labeling practice continues : hearing before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Committee, House of Representatives, Ninety-sixth Congress, second session, March 6, 1980
- "Man-in-the-plant", FDA's failure to regulate deceptive drug labeling : hearings before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-fifth Congress, second session, September 8 and 12, 1978
- A system overwhelmed : the avalanche of imported, counterfeit, and unapproved drugs into the U.S. : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, first session, June 24, 2003
- Acceptable risks : politics, policy, and risky technologies
- Access to unapproved drugs : FDA policies on compassionate use and emergency use authorization
- Addressing the FDA's performance, efficiency, and use of resources : hearings of the Committee on Labor and Human Resources, United States Senate, One Hundred Fifth Congress, first session ... March 19 and April 11, 1997
- Advancing regulatory science for medical countermeasure development : workshop summary
- Advancing the discipline of regulatory science for medical product development : an update on progress and a forward-looking agenda : workshop summary
- Adverse event reporting system for dietary supplements : an inadequate safety valve
- Advisory Committee on the Food and Drug Administration : final report : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Second Congress, first session, on reviewing the Advisory Committee on the Food and Drug Administration report on the current state of FDA, and its recommendations to strengthen FDA, May 15, 1991
- Agriculture and related agencies : FY2018 appropriations
- Alimentos seguros : cómo lo logra un equipo
- Amending the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients : report together with additional views (to accompany S. 2394)
- Amendments to Food and Drug Act : hearings before the United States Senate Committee on Interstate and Foreign Commerce, Subcommittee on S. 1190 and H.R. 4071, Eightieth Congress, second session, on Apr. 17, 1948
- Amparando la pureza de la sangre : las múltiples capas protectoras de la FDA para la sangre donada
- An effective defense against breast cancer : FDA's mammography quality standards program
- Anesthesia machine failures : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-eighth Congress, second session, September 26, 1984
- Animal Drug Amendments of 1965 : hearings before the United States House Committee on Interstate and Foreign Commerce, Subcommittee on Public Health and Welfare, Eighty-Ninth Congress, second session, on June 13, 1966
- Annual reports 1950-1974 on the administration of the Federal food, drug, and cosmetic act and related laws
- Assessment of the Commissioner's report of October 1975
- Assuring data quality and validity in clinical trials for regulatory decision making : workshop report
- Banning of the drug Laetrile from interstate commerce by FDA : hearing before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, United States Senate, Ninety-fifth Congress, first session ... July 12, 1977
- Banning of the drug Laetrile from interstate commerce by FDA : hearing before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, United States Senate, Ninety-fifth Congress, first session ... July 12, 1977
- Biologics and Biosimilars : Background and Key Issues
- Biomedical politics
- Blood banking and regulation : procedures, problems, and alternatives
- Bottled water regulation : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, April 10, 1991
- Brain-disabling treatments in psychiatry : drugs, electroshock, and the psychopharmaceutical complex
- Building a 21st century FDA : proposals to improve drug safety and innovation : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, second session, on examining proposals to improve drug safety and innovation, and S. 3807, to amend the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act to improve drug safety and oversight, November 16, 2006
- Building a national framework for the establishment of regulatory science for drug development : workshop summary
- Building a national framework for the establishment of regulatory science for drug development : workshop summary
- Butter Quality Standards Volume 1
- By prescription only ; : a report on the roles of the United States Food and Drug Administration, the American Medical Association, pharmaceutical manufacturers, and others in connection with the irrational and massive use of prescription drugs that may be worthless, injurious, or even lethal
- Cancer patient access to unapproved treatments : hearing before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fourth Congress, second session, February 29, 1996
- Challenges for the FDA : the Future of Drug Safety : Workshop Summary
- Challenges for the FDA : the future of drug safety : workshop summary
- Chemical risk assessment : selected federal agencies' procedures, assumptions, and policies : report to congressional requesters
- Chemicals in food products : hearings before the House Select Committee to Investigate the Use of Chemicals in Food Products, House of Representatives, eighty-first Congress, second session, created pursuant to H. Res. 323. Washington: September 14, 15, 19, and 21, 1950; Chicago: November 15, 16, and 17, 1950; Washington: November 28, 29, 30, December 1, 5, 6, 7, 8, 11, 12, 13, 14, and 15, 1950
- Ciencia en la FDA : la base de la protección de la salud pública ; la nueva tecnología, el reto mayor a la FDA
- Clarification of Dr. Goddard's Views on Marihuana : hearings before the United States House Committee on Interstate and Foreign Commerce, Ninetieth Congress, first session, on Nov. 8, 1967
- Clinical trial subjects : adequate FDA protections? : hearing before the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, second session, April 22, 1998
- Commission on Dietary Supplement Labels report to the President, Congress, and the Secretary of the Department of Health and Human Services
- Compilation of laws enforced by the U.S. Food and Drug Administration and related statutes
- Complementary and alternative medicine in government-funded health programs : hearing before the Committee on Government Reform House of Representatives, One Hundred Sixth Congress, first session, February 24, 1999
- Confronting cancer : FDA's long fight against America's bane
- Consumer protection at the Food and Drug Administration : hearing before the Ad Hoc Subcommittee on Consumer and Environmental Affairs of the Committee on Governmental Affairs, United States Senate, One Hundred Second Congress, first session, September 27, 1991
- Continuing concerns over imported pharmaceuticals : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, June 7, 2001
- Council on Competitiveness and FDA plans to alter the drug approval process at FDA : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, second session, March 19, 1992
- Cómo obtener las regulaciones de la FDA
- Defendiendo la salud de los animales para proteger al consumidor
- Dietary Supplement Safety Act : how is the Food and Drug Administration doing 10 years later? : hearing before the Oversight of Government Management, the Federal Workforce, and the District of Columbia Subcommittee of the Committee on Governmental Affairs, United States Senate, One Hundred Eighth Congress, second session, June 8, 2004
- Dietary supplement labels : key elements
- Dietary supplements : a framework for evaluating safety
- Dietary supplements : companies may be difficult to locate in an emergency
- Dietary supplements : structure/function claims fail to meet federal requirements
- Dietary supplements : uncertainties in analyses underlying FDA's proposed rule on ephedrine alkaloids : report to the chairman and ranking minority member, Committee on Science, House of Representatives
- Diminished capacity : can the FDA assure the safety and security of the nation's food supply? : Hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session
- Discussion draft of the Food and Drug Administration Globalization Act legislation : device and cosmetic safety provisions : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, May 14, 2008
- Discussion draft of the Food and Drug Administration Globalization Act legislation : drug safety : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, May 1, 2008
- Discussion draft of the Food and Drug Administration Globalization Act legislation : drug safety : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, May 1, 2008
- Does nitrite cause cancer? : concerns about validity of FDA-sponsored study delay answer : report
- Domestic food safety : FDA could improve inspection program to make better use of resources : report to the chairman, Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- Drug Industry Antitrust Act : hearings before the United States House Committee on the Judiciary, Subcommittee on Antitrust, Eighty-Seventh Congress, second session, on May 17, 18, 23, 24, 1962
- Drug Safety : hearings before the United States House Committee on Government Operations, Subcommittee on Intergovernmental Relations, Eighty-Ninth Congress, first session, on July 20, 22, 27, Aug. 3, 10, Sept. 24, 1965, Part 4
- Drug Safety : hearings before the United States House Committee on Government Operations, Subcommittee on Intergovernmental Relations, Eighty-Ninth Congress, first session, on Mar. 23, 24, May 4, June 8-10, 24, 25, 1965, Part 3
- Drug approval : access to experimental drugs for severely ill patients
- Drug compounding : clear authority and more reliable data needed to strengthen FDA oversight : report to congressional requesters
- Drug compounding: FDA authority and possible issues for Congress : other title information
- Drug efficacy : hearings before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-first Congress, first session
- Drug lag
- Drug lag : Federal Government decision making
- Drug lag : hearing before the Subcommittee on Natural Resources, Agriculture Research, and Environment of the Committee on Science and Technology, U.S. House of Representatives, Ninety-seventh Congress, first session, September 16, 1981
- Drug regulation reform--oversight : hearing before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, second session
- Drug safety
- Drug safety : an update from the Food and Drug Administration : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, second session, March 10, 2010
- Drug safety : most drugs withdrawn in recent years had greater health risks for women
- Drug shortages : FDA's ability to respond should be strengthened : report to congressional requesters
- Drug shortages : FDA's ability to respond should be strengthened : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate
- Drug user fees : enhancing patient access and drug safety : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining enhancing patient access and drug safety relating to prescription drug user fees, including S. 484, March 14, 2007
- Drugs and biologics : hearings before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fourth Congress, first session, May 25, 1995-a consumer's perspective, June 19, 1995-FDA review process
- Drugs@FDA
- El Programa regulatorio para comestibles marinos de la Administración de Drogas y Alimentos
- El proceso del desarrollo de las drogas y la FDA : cómo la agencia asegura que las drogas sean seguras y efectivas
- Enhancing food safety : the role of the Food and Drug Administration
- Enhancing food safety : the role of the Food and Drug Administration
- Ensayos voluntarios de tratamientos médicos en clínicas experimentales
- Ensuring drug safety : where do we go from here? : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, first session, on examining the Food and Drug Administration's process of ensuring drug safety, March 3, 2005
- Ephedra : who is protecting the American consumers? : hearing before the Oversight of Government Management, Restructuring, and the District of Columbia Subcommittee of the Committee on Governmental Affairs, United States Senate, One Hundred Seventh Congress, second session, October 8, 2002
- Examining FDA's role in the regulation of genetically modified food ingredients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, December 10, 2014
- Expanding access to investigational therapies for HIV infection and AIDS : March 12-13, 1990, conference summary
- Exploring the black box : framing in print coverage of antidepressants and depression from 2002 to 2006
- FDA : safeguarding America's health
- FDA : the nation's premier consumer protection and health agency
- FDA Export Reform and Enhancement Act of 1995 : hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, first session on S. 593 ... July 13, 1995
- FDA Risk Evaluation and Mitigation Strategies (REMS : description and effect on generic drug development
- FDA and the drug development process : how the agency ensures that drugs are safe and effective
- FDA and the health professional
- FDA and the medical device industry : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, second session, February 26, 1990
- FDA and the medical device industry : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, March 25 and June 3, 1992
- FDA and the veterinarian
- FDA and the veterinarian
- FDA and the veterinarian
- FDA consumer protection activities--FDA reorganization : hearings, Ninety-first Congress, first and second session ..
- FDA drug approval : a lengthy process that delays the availability of important new drugs : summary : report to the Subcommittee on Science, Research, and Technology, House Committee on Science and Technology
- FDA drug approval : review time has decreased in recent years : report to congressional requesters
- FDA enforcement : a summary of H.R. 3642 and S. 2135
- FDA fights rare diseases : new help for patients without treatments
- FDA foreign drug inspection program : a system at risk : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, November 1, 2007
- FDA inspections of domestic food facilities
- FDA issues : hearings before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, first session, risks and benefits of raw milk, February 13, 1985; Emergency Reye's Syndrome Prevention Act of 1985, March 15, 1985; Orphan Drug Act reauthorization, March 20, 1985
- FDA medical product approvals : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, August 8, 1995
- FDA medical product approvals : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, August 8, 1995
- FDA oversight--food inspection : hearings, Ninety-second Congress, first session ..
- FDA policy on home drug testing kits : hearing before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fifth Congress, first session, February 6, 1997
- FDA proposals to ease restrictions on the use and sale of experimental drugs : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, One hundredth Congress, first session, April 29, 1987
- FDA protetects the public health : ranks high in public trust
- FDA regulation of blood safety : notification, recall, and enforcement practices : hearing before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, June 5, 1997
- FDA regulation of blood safety : notification, recall, and enforcement practices : hearing before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, June 5, 1997
- FDA regulation of medical devices, including the status of breast implants : joint hearing before the Subcommittee on Human Resources and Intergovernmental Relations and the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, August 1, 1995
- FDA regulation of soft contact lenses : hearing before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, second session, December 12, 1980
- FDA regulation of the new drug "Serc" : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-second Congress, second session
- FDA regulation of tobacco products
- FDA resources : comprehensive assessment of staffing, facilities, and equipment needed : report to congressional requesters
- FDA review times : statement of Mary R. Hamilton, Director of Program Evaluation in Human Services Areas, Program Evaluation and Methodology Division, before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives
- FDA user fees : current measures not sufficient for evaluating effect on public health : report to the Chairman, Human Resources and Intergovernmental Relations Subcommittee, Committee on Government Operations, House of Representatives
- FDA's approach to reviewing over-the-counter drugs is reasonable, but progress is slow : report to the Congress
- FDA's continuing failure to regulate health claims for foods : hearings before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred First Congress, first session, October 31 and November 9, 1989
- FDA's drug and device review process : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, February 6, 1992
- FDA's drug approval process : up to the challenge? : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, first session, on examining Food and Drug Administration's (FDA) drug approval process, focusing on FDA's drug approval process after a sponsor demonstrates that their benefits outweigh their risks for a specific population and use, and that the drug meet [sic] meets standards for safety and efficacy, March 1, 2005
- FDA's enforcement authorities for foods : are they adequate?
- FDA's foreign drug inspection program : weaknesses place Americans at risk : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, April 22, 2008
- FDA's generic drug application policy : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, second session, July 28, 1988
- FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session
- FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session
- FDA's generic drug approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session
- FDA's generic drug enforcement and approval process : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, March 7 and June 5, 1991
- FDA's global shield for American consumers : the agency acts worldwide to ensure high quality imports
- FDA's growing responsibilities for the year 2000 and beyond
- FDA's growing responsibilities for the year 2001 and beyond
- FDA's prescription to over-the-counter drug switch : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-eighth Congress, first session on the Food and Drug Administration's policies and procedures in switching drugs from prescription to over-the-counter status, June 6, 1983
- FDA's regulation of Zomax : hearings before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-eighth Congress, first session, April 26 and 27, 1983
- FDA's regulation of animal drug residues in milk : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred First Congress, second session, February 6, 1990
- FDA's regulation of gentian violet appears reasonable : summary : report
- FDA's regulation of the dietary supplement L-tryptophan : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, first session, July 18, 1991
- FDA's regulation of the dietary supplement L-tryptophan : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, first session, July 18, 1991
- FDA's regulation of the drug "Triazure" : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-fourth Congress, second session, October 27, 1976
- FDA's regulation of the marketing of unapproved new drugs : the case of E-Ferol vitamin E aqueous solution : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-eighth Congress, second session, May 4, 1984
- FDA's regulation of the new drug Suprol : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, One Hundredth Congress, first session, May 27, 1987
- FDA's regulation of the new drug Versed : hearings before a subcommittee of the Committee on Government Operations, House of Representatives, One Hundredth Congress, second session, May 5 and 10, 1988
- FDA's role in the evaluation of Avandia's safety : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, June 6, 2007
- FDA-approved bargain drugs : generic products must meet high standards
- Federal Hazardous Substances Labeling Act : hearing before a subcommittee of the Committee on Interstate and Foreign Commerce, House of Representatives, Eighty-sixth Congress, second session, on H.R. 5260, a bill to regulate the interstate distribution and sale of packages of hazardous substances intended or suitable for household use, March 14, 1960
- Federal oversight of animal use in research facilities
- Federal regulation of medical devices : problems still to be overcome : report to the Congress
- Fighting foodborne illness : how FDA helps keep the food supply safe
- Filthy food, dubious drugs, and defective devices : the legacy of FDA's antiquated statute : a staff report
- Final report of the Advisory Committee on the Food and Drug Administration
- Food additives and packaging
- Food and Drug Administration : FDA faces challenges meeting its growing medical product responsibilities and should develop complete estimates of its resource needs : report to congressional requesters
- Food and Drug Administration : effect of user fees on drug approval times, withdrawals, and other agency activities : report to the chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate
- Food and Drug Administration : regulation of tobacco products : report to congressional requesters
- Food and Drug Administration : reorganization and historical perspectives
- Food and Drug Administration Amendments Act of 2007 : report together with additional views (to accompany H.R. 2900) (including cost estimate of the Congressional Budget Office)
- Food and Drug Administration Amendments Act of 2007 : report together with additional views (to accompany H.R. 2900) (including cost estimate of the Congressional Budget Office)
- Food and Drug Administration Modernization Act of 1997 : FDA plan for statutory compliance
- Food and Drug Administration Procedures for the Selection of Laboratory Sites : hearings before the United States House Committee on Government Operations, Subcommittee on Intergovernmental Relations, Ninetieth Congress, first session, on June 28, 1967
- Food and Drug Administration act : hearing, Ninety-second Congress, second session, on H.R. 15315 Ninety-second Congress, second session, on H.R. 15315 ... June 9, 1972
- Food and Drug Administration advisory committees
- Food and Drug Administration advisory committees
- Food and Drug Administration oversight : hearings before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session
- Food and Drug Administration practice and procedure, 1975 : joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, first session ... January 28, 1975, the Dalkon Shield, January 29, 1975, Bureau of Veterinary Medicine and Bureau of Foods
- Food and Drug Administration practice and procedure, 1976 : joint hearing before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, second session ... July 20, 1976
- Food and Drug Administration's food labeling regulation : its effect on small business : hearings before the Subcommittee on Special Small Business Problems of the Committee on Small Business, House of Representatives, Ninety-fifth Congress, second session ... July 13, August 3, 1977, and March 15, 1978
- Food and Drug Administration's food labeling regulation : its effect on small business | hearings before the Subcommittee on Special Small Business Problems of the Committee on Small Business, House of Representatives, Ninety-fifth Congress, second session ... July 13, August 3, 1977, and March 15, 1978
- Food and Drug Administration's program for regulating imported products needs improving : Department of Health, Education, and Welfare, Department of the Treasury : report to the Congress
- Food and Drug Administration's regulation of dietary supplements : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Third Congress, first session, July 20, 1993
- Food and Drug enforcement standards for medical devices : joint hearing before the Subcommittee on Human Resources and Intergovernmental Relations and the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, September 14, 1995
- Food and Drug enforcement standards for medical devices : joint hearing before the Subcommittee on Human Resources and Intergovernmental Relations and the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, September 14, 1995
- Food and cosmetic provisions of the Food and Drug Administration Globalization Act discussion draft legislation : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, April 24, 2008
- Food import inspection : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, first session, July 19 and September 28, 1989
- Food labelling : the FDA's role in the selection of healthy foods
- Food safety : FDA can better oversee food imports by assessing and leveraging other countries' oversight resources : report to congressional committees
- Food safety : FDA's use of faster tests to assess the safety of imported foods : report to congressional requesters
- Food safety : actions needed by USDA and FDA to ensure that companies promptly carry out recalls : report to congressional requesters
- Food safety : federal efforts to ensure the safety of imported foods are inconsistent and unreliable : report to the Chairman, Permanent Subcommittee on Investigations, Committee on Governmental Affairs, U.S. Senate
- Food safety : federal oversight of shellfish safety needs improvement : report to the Committee on Agriculture, Nutrition, and Forestry, U.S. Senate
- Food safety : improvements needed in overseeing the safety of dietary supplements and "functional foods" : report to congressional committees
- Food safety and imports : an analysis of FDA food-related import refusal reports
- Food safety and quality : FDA surveys not adequate to demonstrate safety of milk supply : report to the chairman, Human Resources and Intergovernmental Relations Subcommittee, Committee on Government Operations, House of Representatives
- Food safety and quality : innovative strategies may be needed to regulate new food technologies : report to the Chairman, Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- Food safety progress report : fiscal year 2000
- Food tampering : FDA's actions on Chilean fruit based on sound evidence : report to the ranking minority member, Committee on Foreign Relations, U.S. Senate
- Food, Drug, Cosmetic, and Device Enforcement Authorities Act : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Second Congress, second session, on S. 2135 ... May 19, 1992
- Food, Drug, Cosmetic, and Device Enforcement Authorities Act : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Second Congress, second session, on S. 2135 to amend the Federal Food, Drug, and Cosmetic Act to enhance the enforcement authority of the Food and Drug Administration, and for other purposes, May 19, 1992
- Food, drug, cosmetic, and device enforcement amendments : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, on H.R. 2597, a bill to amend the Federal Food, Drug, and Cosmetic Act to enhance the enforcement authority of the Food and Drug Administration, July 17, 1991
- Foods and biotechnology : FDA policy on foods derived from new plant varieties
- Foods and biotechnology : FDA's regulatory policy proceedings of a seminar July 22, 1992
- For consumers
- From test tube to patient : new drug development in the United States
- Generic drug enforcement : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, on H.R. 2454 ... June 26, 1991
- Global engagement
- Grain sanitation program of the Food and Drug Administration, U.S. Department of Health, Education, and Welfare
- Grain-sanitation program of the Food and Drug Administration. : Hearings ... Eighty-third Congress, first session, on implementation of grain-sanitation program of the Food and Drug Administration with respect to insect infestation of wheat, March 10 and 11, 1953
- Guardando los víveres de la nación en lugar seguro : gran trabajo de la FDA
- Guidance for industry : formal meetings between the FDA and sponsors or applicants
- Guidance for industry, FDA staff, and FDA-accredited third parties, Manufacturer's notification of the intent to use accredited person under the accredited person inspection program authorized by Section 228 of the Food and Drug Administration Amendments Act of 2007 (FDAAA)
- Hard to swallow : FDA enforcement program for imported food : a staff report
- Health services and research : hearings before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, first session, on ... H.R. 1426, March 8, 1985 ... H.J. Res. 136, March 29, 1985, ... H.R. 2026, April 25, 1985
- Hearing on Chlorofluorocarbon Effects and Regulations
- History of the United States Food administration, 1917-1919
- How FDA approves drugs and regulates their safety and effectiveness
- How accurate is the FDA's monitoring of supplements like ephedra? : hearing before the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session, May 27, 1999
- Human subject protection : the FDA's role in a system of safeguards
- Human tissue banks : FDA taking steps to improve safety, but some concerns remain : report to the ranking minority member, Committee on Commerce, House of Representatives
- Impact of medical device regulation on jobs and patients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, first session, February 17, 2011
- Implementing the 21st Century Cures Act : an update from FDA and NIH : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, November 30, 2017
- Imported drugs : U.S.-EU (European Union) mutual recognition agreement on drug inspections : hearing before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fifth Congress, second session, October 2, 1998
- Imported foods : opportunities to improve FDA's inspection program : report to the chairman, Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- Infant formula : our children need better protection : report together with dissenting views
- Information sheets : guidance for institutional review boards and clinical investigators : 1998 update
- Integration of FDA and NIOSH processes used to evaluate respiratory protective devices for health care workers : proceedings of a workshop
- Interim reports
- Is the FDA protecting patients from the dangers of silicone breast implants? : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred First Congress, second session, December 18, 1990
- Keeping America's families safe : reforming the food safety system : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eleventh Congress, first session ... October 22, 2009
- Keeping America's families safe : reforming the food safety system : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eleventh Congress, first session, on examining keeping America's families safe, focusing on reforming the food safety system, October 22, 2009
- Keeping the nation's food supply safe : FDA's big job well done
- La FDA combate las enfermedades raras : nueva ayuda para pacientes sin tratamientos
- La FDA protege la salud pública : ocupa lugar alto en la confianza pública
- La lucha contra el cáncer : la larga batalla de la FDA contra la mayor aflicción de América
- La protección del ser humano : el papel de la FDA en un sistema de seguridad
- La urgencia para mejorar la seguridad del paciente : la FDA recibe anualmente más de 350,000 reportes de casos adversos
- Las drogas baratas aprobadas por la FDA : los productos genéricos deben satisfacer altos niveles
- Las vacunas proveen proteción efectiva y la FDA se asegura de que sean sanas
- Los esfuerzos de la FDA por el consumidor Americano : la agencia en busca de alta calidad en las importaciones
- Luchando contra la contaminación : cómo la FDA mantiene sanos los alimentos
- Markup Session [on Agriculture and Related Agencies Appropriations]
- Medical Device Regulatory Modernization Act of 1997 : report, together with additional views (to accompany H.R. 1710) (including cost estimate of the Congressional Budget Office)
- Medical device approval letter : the monthly guide to getting 510(k)s and PMA applications approved
- Medical device regulation : too early to assess European system's value as model for FDA : report to the Chairman, Committee on Labor and Human Resources, U.S. Senate
- Medical device reporting : improvements needed in FDA's system for monitoring problems with approved devices : report to congressional committees
- Medical device user fees : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Third Congress, second session, on H.R. 4728, a bill to amend the Federal Food, Drug, and Cosmetic Act to authorize a device application fee, and for other purposes, July 14, 1994
- Medical devices : FDA can improve oversight of tracking and recall systems : report to the Subcommittee on Oversight and Investigations, Committee on Commerce, House of Representatives
- Medical devices : FDA faces challenges in conducting inspections of foreign manufacturing establishments : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives
- Medical devices : FDA should take steps to ensure that high-risk device types are approved through the most stringent premarket review process : report to congressional addressees
- Medical devices : FDA's implementation of the medical device reporting regulation : report to the Chairman, Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representatives
- Medical devices : status of FDA's program for inspections by accredited organizations : report to congressional committees
- Medical devices : technological innovation and patient/provider perspectives : hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives, One Hundred Fifth Congress, first session, May 30, 1997
- Medical devices and the public's health : the FDA 510(k) clearance process at 35 years
- Medical letter on the CDC & FDA
- Medical technology development and commercialization : hearing before the Subcommittee on Technology of the Committee on Science, U.S. House of Representatives, One Hundred Fourth Congress, first session, November 2, 1995
- Mejor cuidado de la salud con dispositivos médicos de calidad : FDA a la cabeza en tecnología de dispositivos médicos
- Mejorando la salud pública : fomentando la venta y el uso de drogas efectivas
- Mercury in medicine--are we taking unnecessary risks? : hearing before the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, second session, July 18, 2000
- Milestones in U.S. food and drug law history
- Mission possible : how FDA can move at the speed of science
- New drug approval : FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints : report to the Ranking Member, Committee on Finance, U.S. Senate
- New drug approval : FDA's consideration of evidence from certain clinical trials : report to congressional requesters
- New hope for the mentally retarded : stymied by the FDA
- New products to treat diabetes : FDA helps counter a major public health threat
- Nuevos productos para tratar la diabetes : la FDA ayuda a combatir una amenaza mayor a salud pública
- Nutrition and Human Needs : hearings before the United States Senate Select Committee on Nutrition and Human Needs, Ninetieth Congress, first session, on July 22-25, 1969, Part 13B, Nutrition and Private Industry
- Nutrition labeling : FDA and USDA need a coordinated assessment of food label accuracy : report to the Chairman, Subcommittee on Nutrition and Investigations, Committee on Agriculture, Nutrition, and Forestry, U.S. Senate
- Off-label drug use and FDA review of supplemental drug applications : hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996
- Overdose : how excessive government regulation stifles pharmaceutical innovation
- Oversight of FTC's shared responsibilities : hearing before the Subcommittee on Transportation and Hazardous Materials of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, concerning advertising and labeling issues with the Bureau of Alcohol, Tobacco, and Firearms, the Environmental Protection Agency, and the Food and Drug Administration, November 21, 1991
- Oversight of NIH and FDA : bioethics and the adequacy of informed consent : hearing before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, May 8, 1997
- Oversight of NIH and FDA : bioethics and the adequacy of informed consent : hearing before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, May 8, 1997
- Oversight of clinical investigators : action needed to improve timeliness and enhance scope of FDA's debarment and disqualification processes for medical product investigators : report to congressional requesters
- Oversight of the Food and Drug Administration's progress in reducing unnecessary paperwork burdens upon small business : hearing before the Subcommittee on Government Programs of the Committee on Small Business, House of Representatives, One Hundred Fourth Congress, second session, Washington, DC, July 24, 1996
- Oversight of the new drug review process and FDA's regulation of Merital : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-ninth Congress, second session, May 22, 1986
- Patient access to alternative treatments : beyond the FDA : hearings before the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, second session, February 4 and 12, 1998
- Patient access to alternative treatments : beyond the FDA : hearings before the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, second session, February 4 and 12, 1998
- Pediatric drug research : Food and Drug Administration should more efficiently monitor inclusion of minority children
- Pediatric medical devices : provisions support development, but better data needed for required reporting : report to congressional committees
- Perspectives on risk and regulation : the FDA at 100
- Pipeline drugs : proposed remedies for relief in the Drug Patent Term Restoration Review Procedure Act of 1999 : hearing before the Committee on the Judiciary, United States Senate, One Hundred Sixth Congress, first session, on S. 1172 ... August 4, 1999
- Postmarketing surveillance of prescription drugs
- Potential transmission of spongiform encephalopathies to humans : the Food and Drug Administration's (FDA) ruminant to ruminant feed ban and the safety of other products : hearing before the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, January 29, 1997
- Preclinical and clinical testing by the pharmaceutical industry, 1975 : joint Hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare, and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, first session-second session
- Preclinical and clinical testing by the pharmaceutical industry, 1976 : joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, second session, on examination of the process of drug testing and FDA's role in the regulation and conditions under which such testing is carried out ..
- Preclinical and clinical testing by the pharmaceutical industry, 1977 : hearing before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, United States Senate, Ninety-fifth Congress, first session
- Preclinical and clinical testing by the pharmaceutical industry, 1977 : hearing before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, United States Senate, Ninety-fifth Congress, first session ..
- Prescription Drug User Fee Act (PDUFA : 2017 reauthorization as PDUFA VI
- Prescription drugs : FDA oversight of direct-to-consumer advertising has limitations
- Prescription drugs : improvements needed in FDA's oversight of direct-to-consumer advertising : report to congressional requesters
- Prescription drugs : many factors affected FDA's approval of selected "pipeline" drugs : report to congressional requesters
- Problems with FDA monitoring for animal drug residues : is our milk safe? : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, second session, August 5, 1992
- Problems with FDA's regulation of the antiarrhythmic drugs Tambocor and Enkaid : hearing before the Human Resources and Intergovernmental Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, first session, April 10, 1991
- Promotion of drugs and medical devices for unapproved uses : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, first session, June 11, 1991
- Promotion of drugs and medical devices for unapproved uses : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, first session, June 11, 1991
- Protecting America's health : the FDA, business, and one hundred years of regulation
- Public advisory committees : authority, structure, functions, members
- Public health effectiveness of the FDA 510(k) clearance process : balancing patient safety and innovation : workshop report
- Public health effectiveness of the FDA 510(k) clearance process : balancing patient safety and innovation : workshop report
- Public health effectiveness of the FDA 510(k) clearance process : measuring postmarket performance and other select topics : workshop report
- Public health effectiveness of the FDA 510(k) clearance process : measuring postmarket performance and other select topics : workshop report
- Punitive damages : tort reform and FDA defenses : hearings before the Committee on the Judiciary, United States Senate, One Hundred Fourth Congress, first session, on S. 671 ... S. 672 ... April 4 and July 26, 1995
- Quality of scientific evidence in FDA regulatory decisions : the adoption of an antismoking warning in oral contraceptive pill labeling : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-fifth Congress, second session, October 4, 1978
- Recall procedures of the Food and Drug Administration : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-second Congress, first session. March 29, 1971
- Regulation of new drug R. & D. by the Food and Drug Administration, 1974 : joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare, and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-third Congress, second session ... September 25 and 27, 1974
- Regulation of new drug R. & D. by the Food and Drug Administration, 1974 : joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare, and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-third Congress, second session ... September 25 and 27, 1974
- Regulatory policies of the Food and Drug Administration : hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-first Congress, second session, June 9, 1970
- Reinventing regulation of drugs and medical devices
- Reinventing the regulation of cancer drugs : accelerating approval and expanding access
- Reinventing the regulation of drugs made from biotechnology
- Relief of Electronic Medical Foundation
- Relief of the Smith Canning Company
- Reputation and power : organizational image and pharmaceutical regulation at the FDA
- Restoring FDA's ability to keep America's families safe : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, second session ... April 24, 2008
- Restoring FDA's ability to keep America's families safe : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, second session, on examining the U.S. Food and Drug Administration, focusing on its ability to ensure the safety of food and the drug supply in the United States, April 24, 2008
- Review of the fialuridine (FIAU) clinical trials
- Revitalizing new product development from clinical trials through FDA review : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, second session, on S. 1477 ... February 21, 1996
- Revitalizing new product development from clinical trials through FDA review : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, second session, on S. 1477 ... February 21, 1996
- Right to Try : access to investigational drugs
- Role of commissioner of food and drugs : hearing before the Committee on Labor and Human Resources, United States Senate, One Hundred Second Congress, first session, on examining the role of the current commissioner of the Food and Drug Administration, March 6, 1991
- Role of commissioner of food and drugs : hearing before the Committee on Labor and Human Resources, United States Senate, One Hundred Second Congress, first session, on examining the role of the current commissioner of the Food and Drug Administration, March 6, 1991
- Science at the FDA : the mainstay of public health protection, new technology is FDA's greatest challenge
- Single-use medical devices : little available evidence of harm from reuse, but oversight warranted : report to congressional requesters
- Soft contact lens solutions : oversight of FDA : hearing before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, second session, July 1, 1980
- Strengthening a workforce for innovative regulatory science in therapeutics development : workshop summary
- The FDA
- The FDA Commission : the delegation of authority to state and local authority
- The FDA Commission : the delegation of authority to state and local officials
- The FDA and the future of American biomedical and food industries : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, first session, on examining activities of the Food and Drug Administration focusing on the challenges and opportunities facing the pharmaceutical, biotech, medical device, and food industries, and FDA's regulation of these industries, April 5 and 6, 1995
- The FDA museum : opening exhibit, administering the first Federal Food and Drugs act, passed June 30, 1906
- The FDA's regulation of silicone breast implants : a staff report
- The Food & drug letter
- The Food and Drug Administration's critical mission and challenges for the future : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, May 1, 2007
- The Food and Drug Administration's critical mission and challenges for the future : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, May 1, 2007
- The Food, Drug, and Insecticide Administration ; : its history, activities and organization
- The Impact of the Food and Drug Administration on our society : a fiftieth anniversary panorama
- The NDA book
- The SUPPORT for Patients and Communities Act (P.L. 115-271 : Food and Drug Administration and controlled substance provisions
- The adequacy of FDA to assure the safety of the nation's drug supply : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, February 13, March 22, 2007
- The adequacy of FDA to assure the safety of the nation's drug supply : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, February 13, March 22, 2007
- The challenge to improve patient safety : FDA logs over 350,000 reports of adverse events annually
- The chemical feast : the Ralph Nader study group report on food protection and the Food and Drug Administration
- The dictocrats' attack on health foods and vitamins
- The effect of FDA regulations (GRAS) on plant breeding and processing : papers presented at the annual meeting of the Crop Science Society of America in Las Vegas, Nevada, November, 1973
- The future of drug safety : promoting and protecting the health of the public
- The future of drug safety : promoting and protecting the health of the public
- The mirage of safety : food additives and Federal policy
- The need for FDA regulation of tobacco : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session on examining S. 625, to protect the public health by providing the Food and Drug Administration with certain authority to regulate tobacco products, February 27, 2007
- The need for FDA regulatory reform to protect the health and safety of Americans : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, June 9, 1995
- The philosophy of evidence
- The poison conspiracy
- The regulation of animal drugs by the Food and Drug Administration : hearings before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-ninth Congress, first session, July 24 and 25, 1985
- The regulation of new drugs by the Food and Drug Administration : the new drug review process : hearings before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-seventh Congress, second session, August 3 and 4, 1982
- The risks of prescription drugs
- The role and performance of FDA in ensuring food safety : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, second session, May 6, 2010
- The therapeutic nightmare : a report on the roles of the United States Food and Drug Administration, the American Medical Association, pharmaceutical manufacturers, and others in connection with the irrational and massive use of prescription drugs that may be worthless, injurious or even lethal
- To assess the impact of proposed FDA user fees on small business : hearing before the Committee on Small Business, United States Senate, One Hundred First Congress, first session ... June 13, 1989
- Tobacco legislation and the Food and Drug Administration and smokeless tobacco issues : hearing before the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Fifth Congress, second session, March 17, 1998
- Tobacco legislation and the Food and Drug Administration and smokeless tobacco issues in the proposed settlement : hearing before the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Fifth Congress, second session, March 17, 1998
- U.S. Food and Drug Administration announcement related to certain sleep disorder drugs
- Un centro de la FDA al frente de investigación biomolecular
- Una defensa efectiva contra el cáncer de los senos : la calidad del tipo de programa de mamográfias de la FDA
- Use of advisory committees by the Food and Drug Administration : hearings before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-third Congress, second session
- Use of advisory committees by the Food and Drug Administration : hearings before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-third Congress, second session ...
- User fees for prescription drugs : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, August 10, 1992
- Vaccines provide effective protection and FDA makes sure they are safe
- Washington drug letter
- We want you to know about today's FDA
- When a patient speaks-- : patient representatives to FDA advisory committees : a video presented by the U.S. Food and Drug Administration
- When diets turn deadly : consumer safety and weight-loss supplements : hearing before the Oversight of Government Management, Restructuring, and the District of Columbia Subcommittee of the Committee on Governmental Affairs, United States Senate, One Hundred Seventh Congress, second session, July 31, 2002
- Why volunteer? : clinical trials of medical treatments
- Wilhelm Reich vs. the U.S.A
- Women and health research : ethical and legal issues of including women in clinical studies
- Xenotransplantation : science, ethics, and public policy
- [Relief of] Electronic Medical Foundation
Embed (Experimental)
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.library.missouri.edu/resource/dPNewY5j2eA/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.library.missouri.edu/resource/dPNewY5j2eA/">United States, Food and Drug Administration</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.library.missouri.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.library.missouri.edu/">University of Missouri Libraries</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Concept United States, Food and Drug Administration
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.library.missouri.edu/resource/dPNewY5j2eA/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.library.missouri.edu/resource/dPNewY5j2eA/">United States, Food and Drug Administration</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.library.missouri.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.library.missouri.edu/">University of Missouri Libraries</a></span></span></span></span></div>
